Abstract A17: The dual angiogenesis/heparanase inhibitor PG545 inhibits solid tumor progression in models of breast, prostate and liver cancer: A comparative assessment of once versus twice weekly administration schedules

Edward Hammond, Keith Dredge, Paul Handley et al.|Molecular Cancer Therapeutics|2009

Cited by 3